The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Metabotropic Glutamate Receptor 1 and Glutamate Signaling in Human Melanoma
Open accessAbstract
Recently, several laboratories have started to investigate the involvement of glutamate signaling in cancer. In previous studies, we reported on a transgenic mouse model that develops melanoma spontaneously. Subsequent studies in these mice identified that the aberrant expression of metabotropic glutamate receptor 1 (GRM1) in melanocytes played a critical role in the onset of melanoma. Confirmation of the etiologic role of GRM1 in melanoma development was shown in a second transgenic line with GRM1 expression under the regulation of a melanocyte-specific dopachrome tautomerase promoter. Ectopic expression of GRM1 was also detected in a subset of human melanoma cell lines and biopsies, suggesting that aberrant expression of GRM1 in melanocytes may contribute to the development of human melanoma. GRM1, a seven-transmembrane domain G protein–coupled receptor, is normally expressed and functional in neuronal cells, and its ligand, glutamate, is the major excitatory neurotransmitter. Human melanoma cells are shown here to release elevated levels of glutamate, implying a possible autocrine loop. Treatment of GRM1-expressing human melanoma cells with a GRM1 antagonist (LY367385 or BAY36-7620) or a glutamate release inhibitor (riluzole) leads to a suppression of cell proliferation as well as a decrease in levels of extracellular glutamate. Treatment of human melanoma cell xenografts with riluzole for 18 days via p.o. gavage or i.v. injection leads to inhibition of tumor growth by 50% in comparison with controls. These data suggest the importance of glutamate signaling in human melanoma and imply that the suppression of glutamate signaling may be a new target for melanoma therapy. [Cancer Res 2007;67(5):2298–305]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Activation of Stat3 in Human Melanoma Promotes Brain Metastasis
Xie, T.-X., Huang, F.-J., Aldape, K. D., Kang, S.-H., Liu, M., Gershenwald, J. E., Xie, K., Sawaya, R., & Huang, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2674 · Cited by 393
Cited by
Metabotropic glutamate receptors: From the workbench to the bedside
Nicoletti, F., Bockaert, J., Collingridge, G. L., Conn, P. J., Ferraguti, F., Schoepp, D. D., Wroblewski, J. T., & Pin, J. P. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.022 · Cited by 653
Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs
Shim, J. S., & Liu, J. O. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.9224 · Cited by 382
In silico repositioning of approved drugs for rare and neglected diseases
Ekins, S., Williams, A. J., Krasowski, M. D., & Freundlich, J. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.016 · Cited by 288
Zhang, L., Xiao, H., Karlan, S., Zhou, H., Gross, J., Elashoff, D., Akin, D., Yan, X., Chia, D., Karlan, B., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015573 · Cited by 272
Drug repositioning: Progress and challenges in drug discovery for various diseases
Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114239 · Cited by 232
Metadata
- Authors
- Namkoong, J., Shin, S.-S., Lee, H. J., Marín, Y. E., Wall, B. A., Goydos, J. S., & Chen, S.
- Venue
- Cancer Research
- Published
- 2007-03-01
- Volume
- 67
- Issue
- 5
- Pages
- 2298-2305
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2066715779
- Cited by
- 192
- References
- 3
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabotropic Glutamate Receptor 1 and Glutamate Signaling in Human Melanoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-3665
- The paper
- Namkoong, J., Shin, S.-S., Lee, H. J., Marín, Y. E., Wall, B. A., Goydos, J. S., & Chen, S. (2007). Metabotropic Glutamate Receptor 1 and Glutamate Signaling in Human Melanoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-3665
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.